Posted by Michael Wonder on 27 Sep 2022
Tezspire approved in Japan for the treatment of severe asthma
27 September 2022 - Tezspire approved for a broad population of patients with severe asthma with no phenotype or biomarker limitations.
AstraZeneca’s Tezspire (tezepelumab) has been approved in Japan for the treatment of bronchial asthma in patients with severe or refractory disease in whom asthma symptoms cannot be controlled with mid or high dose inhaled corticosteroids and other long-term maintenance therapies.
